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Background: CD4+ T cells are critically important in HIV infection, being both the primary cells infected by HIV
and likely playing a direct or indirect role in helping control virus replication. Key areas of interest in HIV vaccine
research are mechanisms of viral escape from the immune response. Interestingly, in HIV infection it has been
shown that peptide sequence variation can reduce CD4+ T cell responses to the virus, and small changes to
peptide sequences can transform agonist peptides into antagonist peptides.
Results: We describe, at a molecular level, the consequences of antagonism of HIV p24-specific CD4+ T cells.
Antagonist peptide exposure in the presence of agonist peptide caused a global suppression of agonist-induced
gene expression and signaling molecule phosphorylation. In addition to down-regulation of factors associated with
T cell activation, a smaller subset of genes associated with negative regulation of cell activation was up-regulated,
including KFL-2, SOCS-1, and SPDEY9P. Finally, antagonist peptide in the absence of agonist peptide also delivered
a negative signal to T cells.
Conclusions: Small changes in p24-specific peptides can result in T cell antagonism and reductions of both T
cell receptor signaling and activation. These changes are at least in part mediated by a dominant negative signal
delivered by antagonist peptide, as evidenced by up-regulation of negative regulatory genes in the presence of
agonist plus antagonist stimulation. Antagonism can have dramatic effects on CD4+ T cell function and presents
a potential obstacle to HIV vaccine development.
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CD4+ T cells are critically important in HIV infection as
they are the cells that are primarily targeted by HIV and
as well play an important role in the immune response
to HIV infection [1]. In HIV infection it has been dem-
onstrated that peptide variation can reduce the CD4+ T
cell response to the virus [2-4]. Peptides can be grouped
into three different categories, peptide sequences that
elicit full activation phenotypes (agonist sequences),* Correspondence: pnorris@bloodsystems.org
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unless otherwise stated.partial activation phenotypes (partial agonists) [5], and
others that inhibit CD4+ T cell responses (antagonists)
[6]. Typically, the sequences of antagonist peptides are
variations of known agonist peptides [7], for example a
single amino acid change in the minimum epitope of an
agonist. These peptides are referred to as altered peptide
ligands (APLs). Although it is clear that peptide se-
quence is important in T cell activation and antagonism,
the mechanism by which these antagonist peptides work
is unclear. These APLs not only fail to activate virus-
specific T cells, but could potentially mediate escape
from T cell recognition by blocking T cell responses di-
rected to native virus sequence [8-12]. Moreover, KentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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as a potential mechanism for vaccine failure [13].
There are many studies to date looking at various po-
tential mechanisms of T cell antagonism, including but
not limited to systems with T cells expressing dual TCRs
where one TCR can antagonize the other (cross-antag-
onism) [14-20], with most studies supporting the deliv-
ery of a dominant negative signal by antagonist peptides.
Other proposed antagonism mechanisms include com-
petitive inhibition leading to a failure to induce TCR sig-
naling and Ca++ influx [21], and differential or negative
signaling resulting from conformational changes of the
TCR induced by the antagonist ligand [22,23]. There is
also a study showing that T cell antagonism by galectin-1
binding results in truncated TCR signaling and disrupted
lipid raft formation at TCR contact sites [24]. Taken to-
gether, it is apparent the mechanism of TCR antagonism
is likely to vary depending on the model system.
Our earlier studies determined the minimum size epi-
topes from five HIV Gag-specific CD4+ T cell clones
[4,25]. One clone, AC-25, has a minimum epitope 16
amino acids in length, PEVIPMFSALSEGATP (PP16), at
positions 167–182 in Gag. N-terminal truncation of one
amino acid allows for partial activation of T cell clones
and further truncation eliminates activation [4]. Further-
more, a peptide truncated by three C-terminal amino
acids (PEVIPMFSALSEG, PG13) also is non-activating
and acts as an antagonist peptide [26,27]. X-ray diffraction
analysis revealed that the extension of the C-terminal end
of the PP16 peptide outside the peptide/MHC binding
groove allows interaction with the TCR that does not
occur with the truncated peptide, PG13 [27]. The native
full-length epitope (PP16) can be engineered to act as an
antagonist by substituting proline for glycine at position
13, and modeling shows that this eliminates a hinge region
at the glycine and prevents interaction of the C-terminal
portion of the peptide with the TCR [26]. Finally, we pre-
viously demonstrated that the antagonist peptide-MHC
can bind the TCR, but with lower avidity than agonist
peptide-MHC [26]. Given that we know many of the
extracellular events that are associated with T cell antag-
onism in this system, we next wanted to determine the
intracellular signals potentially delivered by cells exposed
to the antagonist peptide. One of the limitations of the
PG13 antagonist model is that we have not examined its
abundance in vivo relative to the PP16 agonist peptide.
However, peptide length-dependent antagonism of T cell
responses has been previously described [28,29], and in a
mouse model endogenous processing and antagonist ac-
tivity of shorter peptides has been demonstrated [28].
In this study we examined the transcriptome and sig-
naling cascade induced by the truncated antagonist pep-
tide PG13. Utilizing CD4+ T cell clones, we showed that
stimulation with the agonist peptide, PP16, in the presenceof the antagonist, PG13, prevented transcriptional up-
regulation of a broad group of activating proteins while
also up-regulating a smaller number of inhibitory gene
products. The majority of the down-regulated genes are
associated with TCR signaling and pro-inflammatory
cytokine production. We also observed truncated STAT
phosphorylation and reduced production of multiple in-
flammatory cytokines and chemokines. We conclude
that the truncated peptide acted as an antagonist to full
length peptide through down-regulation of the T cell ac-
tivation pathway, ultimately leading to global suppres-
sion of T cell signaling and function.
Results
Truncated STAT signaling after antagonist exposure
To understand the initial activation pathways disrupted in
the presence of the antagonist peptide, the phosphoryl-
ation state of key molecules in the T cell activation path-
way was measured [30,31]. Intracellular staining with
antibodies specific for phosphorylated forms of proteins
in the activation cascade allows longitudinal analysis of
T cells after antigenic stimulation. We compared un-
stimulated T cell clones with clones stimulated with B
cells pulsed with agonist (Ag) or antagonist (Ant) alone
or agonist plus antagonist (Ag + Ant). Both Ag and Ag +
Ant conditions induced comparable degrees of STAT-3
and STAT-5 phosphorylation two hours after stimulation,
but phosphorylation was sustained at high levels only after
Ag alone stimulation (Figure 1). These data suggest that
antagonists do not completely block T cell activation, but
rather truncate or attenuate the activation signal prior to
full T cell activation.
Inflammatory cytokines and chemokines are broadly
down-regulated by antagonist exposure
Because the STAT-3 and STAT-5 phosphorylation data
indicated incomplete activation of the T cells, we sought
to determine what other T cell factors were decreased after
Ag +Ant stimulation. Unstimulated T cells were compared
to T cells stimulated with peptide pulsed B cells in the
presence or absence of the antagonist peptide over an
18-hour time course (Figure 2A, B). At each time point,
supernatants were harvested and measured for 39 se-
creted cytokines and chemokines by multiplex testing.
Total area under the curve was determined for each of
the cytokines secreted for the first four hours post-
stimulation (see Methods). Cytokine/chemokine con-
centrations fell into three clusters, AUC > 500, AUC >
100, and AUC > 10 (Figure 2C). The highest expressed
group (AUC > 500) was comprised of pro-inflammatory
cytokines typically associated with T cell activation. As
expected, there was a substantial decrease in IFN-γ pro-
duction (5.7-fold) in the Ag + Ant treated samples. In
addition, there were substantial decreases in several
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Figure 1 Phosflow detection of STAT-3 and STAT-5. STAT-3 and −5 were measured by flow cytometry in CD4+ T cell clones co-incubated
with peptide (dotted = Ant, black = Ag, grey = Ag + Ant) or mock (dashed = no peptide) pulsed B cells. Panels A and B are one representative
experiment of five. Bottom panels (C) show fold change in mean fluorescence intensity (MFI) of STAT-3 and −5 from five experiments; circle = Ag,
square = Ag + Ant, triangle = Ant, error bars show standard error of the mean (SEM).
Jacobs et al. Retrovirology 2014, 11:57 Page 3 of 16
http://www.retrovirology.com/content/11/1/57inflammatory cytokines, including MIP-1α (3.1-fold) and
TNF-α (5.5-fold). The second group (AUC > 100) con-
sisted mostly of growth and chemotactic factors, and al-
though not expressed to the same degree as the pro-
inflammatory cytokines, there were substantial decreases
in expression in the Ag +Ant samples including GM-CSF
(3.9-fold), IL-8 (3.1-fold), and IP-10 (3.1-fold). Also of
note, a sizeable decrease in the regulatory cytokine IL-10
was detected (3.1-fold). The third group (AUC > 10) in-
cluded chemotactic factors and the common γ-chain cyto-
kines IL-2 and IL-7. Despite the low level secretion of
these factors, several noteworthy decreases in expression
were detected in the Ag +Ant samples, including IL-13
(3.4-fold), IL-7 (3.9-fold) and fractalkine (2.4-fold). We
questioned whether T cell antagonism would selectively
block pathways of activation (e.g. bias towards a Th2response) and found that IFN-γ, TNF-α, and IL-10 were
more suppressed and sCD40L was less suppressed than
the rest of the cytokines measured in the Ag +Ant sam-
ples (Figure 2D). The degree of suppression ranged within
the 95% confidence interval of 49% to 73% suppression for
most of the cytokines, and it did not appear that the an-
tagonist peptide selectively blocked a specific program of
cytokine secretion, consistent with global suppression of T
cell function by the antagonist.
Antagonism causes global suppression of T cell activation
To complement the functional studies, we surveyed ex-
pression of a broad array of over 46,000 genes after stimu-
lation with the Ag, Ant, or Ag + Ant peptides. To
maximize the signal derived from T cells, it would be opti-
mal to exclude B cells from the gene array expression
Figure 2 Multiplex detection of secreted cytokines. Secreted cytokines and chemokines following co-culture of CD4+ T cells with peptide or
mock pulsed B cells were detected by multiplex assay. (A) and (B) Cytokine levels were tested in CD4+ T cell supernatants at serial time points
over 18 hours with data for IFN-γ and TNF-α shown for two experiments (Ant treatment was run once). (C) Total area under the curve for
secretion of each cytokine over 4 hours post-stimulation was calculated as described in Materials and Methods. Mean values from two replicate
experiments are shown; error bars show SEM. (D) Percent suppression of agonist-induced cytokine suppression by addition of antagonist peptide.
Suppression was calculated based on the AUC of cytokines four hours after stimulation. Dashed lines indicated the 95% confidence interval of
the mean of 2 experiments, error bars show SEM.
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antigen presenting cells has been described previously
[32], and we found that the AC-25 clones could present
antigen to themselves (Figure 3). Given that the levels of
stimulated T cells were not significantly different in the
absence of B cells, B cells were excluded from the gene
array experiments. We compared unstimulated T cells
with T cells stimulated by Ag (PG16) in the presence or
absence of Ant (PG13) for four hours, followed by mRNA
extraction. Extracted mRNA was hybridized to an Illu-
mina BeadArray, and the results were analyzed using IPA
software. Genes with expression levels that differed by
1.5-fold or more with a p-value of <0.05 clustered into
two distinct expression patterns, genes that were up-
regulated in the Ag treatment and genes that were down-
regulated in the Ag + Ant treatment (Figure 4A). Thirty
five genes increased expression with Ag treatment, and
their median expression was significantly higher than both
Ag +Ant treatment as well as Ant alone treatment(Figure 4B). Conversely, a second set of 25 genes down-
regulated in the Ag compared to the Ag +Ant treatment
had significantly higher expression in the Ag + Ant treat-
ment (Figure 4C). These data indicate that not only does
the Ag + Ant treatment block up-regulation of genes trig-
gered by the Ag, but Ag +Ant also up-regulates a subset
of genes specific to its own genetic signature.
Table 1 shows the genes with 2-fold or greater difference
in expression between the Ag and Ag +Ant treatment.
Interestingly, most of the genes indicated are involved in
T cell receptor signaling, including FOS/FOSB, EGR1/2,
MAP3K8, and TAGAP, as well as in pro-inflammatory
cytokine production, including TNFSF9, CCL3l1/3, IL-8,
IFN-γ, and TNF. All of the genes expressed at higher
levels in Ag compared to Ag + Ant treatment showed near
zero levels of expression in the unstimulated cells, and
weak to no induction in Ag +Ant or Ant stimulated cells.
Of the few genes that had decreased expression in the Ag
compared to Ag + Ant condition, most notably CCR7 and
BA
Figure 3 T cell clones can present antigen in the absence of professional antigen presenting cells. T cells were stimulated with Ag
peptide in conditions with T cells alone or T cells and B cells mixed together in culture. Addition of peptide to T cell cultures lacking B cells still
induced (A) proliferation and (B) IFN-γ secretion in the responding T cells at levels not significantly different from T cell cultures containing B cells
(GEE p value >0.05). Proliferation was measured by 3H incorporation and the results are expressed as a stimulation index (counts in stimulated
condition/counts in unstimulated condition). IFN-γ secretion was measured by intracellular staining for IFN-γ expression after stimulation in the
presence of brefeldin A. Data are compiled from five proliferation experiments and three intracellular cytokine staining experiments. Error bars
signify SEM.
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compared to variable baseline expression and was mod-
estly elevated in the Ag + Ant condition but not the Ant
alone condition. Interestingly, SPDEY9P is a negative
regulator of cell cycle progression [33]. These results de-
pict a broad suppression of TCR signaling and T cell acti-
vation, consistent with our previously published results
showing suppression of multiple arms of the immune re-
sponse [26].
Pathway analysis of microarray data
We compared the pathway and functional enrichment
results of the Ag and Ag + Ant treatment and observed
significant differences in biological functions related to
immune cell functions. The functions that scored most
significantly in relation to each set of differentially
expressed genes modulated by the indicated conditions
are shown (Figure 5). For example, the function “activa-
tion of T lymphocytes”, which belongs to the broader
category of Hematological System Development and
Function, had a significant p-value of 2.39×10−19 for Ag
treatment, whereas that same function had a p-value of
6.31×10−4 in the Ag + Ant treatment. Similar differences
were seen in all of the functional categories shown in
Figure 5 between Ag and Ag + Ant treatments. The lar-
ger the bar, the more strongly over-represented those
functions were in the dataset, either up-regulated by the
Ag or down-regulated by the Ant. Therefore, multiple
categories that are related to cellular function and sig-
naling were more strongly over-represented after Ag
treatment compared to after Ag + Ant treatment of the
clones. Furthermore, as shown in Figure 6, four functions(Function of T lymphocytes, Stimulation of Leukocytes,
Lymphocytes, and T Lymphocytes) are predicted to be ac-
tivated with the Ag treatment with z-score >2, whereas
there was not a significant association between these func-
tions and Ag + Ant treatment. With Ant treatment all but
one function were decreased following Ant treatment,
with four functions predicted to have decreased activation
with z-score < −2. Activation of functional pathways was
calculated as a z-score (see Methods), with a z-score >2
or < −2 considered significant [50]. Examining all the acti-
vation z-scores from Figure 6 revealed that activation was
significantly higher after Ag stimulation than after Ag +
Ant or Ant treatments (Figure 5B). Of note, activation z-
scores were suppressed in the Ant condition compared to
the Ag +Ant condition, consistent with the antagonist de-
livering a negative signal independently of the presence of
the agonist peptide.
To further explore how the antagonist peptide influ-
enced T cell function, annotated functions within the
Hematological System Development and Function cat-
egory were selected that were associated specifically
with T lymphocytes. IPA defined functions included:
proliferation of activated T cells, induction of T lympho-
cytes, stimulation of T lymphocytes, function of T lym-
phocytes, and activation of T lymphocytes. A network
of direct and indirect interactions between the 56 mole-
cules associated with at least one of these functions was
built from the annotated functions, and then expression
data from Ag, Ag + Ant, and Ant treatments was over-
laid (Figure 7). When the expression data between the
Ag and Ag + Ant treatments are contrasted, with the ex-


















Figure 4 Genes with 1.5 fold or greater difference in expression between Ag and Ag + Ant. Fold change was calculated and Ag + Ant was
subtracted from Ag treatment. Data were then sorted from highest to lowest and 1.5 fold or greater differences. Replicate values for up-regulated
and down-regulated genes are displayed in a heat map (A). Expression of up-regulated (B) and down-regulated (C) genes with medians from
individual treatments are shown (Unstim = Unstimulated, Ag = Agonist, Ag + Ant = Agonist + Antagonist, Ant = Antagonist alone). p-Values were
determined by Kruskal-Wallis followed by Dunn’s Multiple Comparisons Test, *** = p < 0.001.
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up-regulated by agonist were markedly reduced in ex-
pression when the antagonist peptide was present.
Interestingly, there are several genes that were de-
creased in expression with Ag treatment which were in-
creased in Ag + Ant treatment. These genes include C-C
chemokine receptor 7 (CCR7), Kruppel Like Factor-2
(KFL-2), sphingosine-1 phosphate receptor-1 (S1PR1),
the potassium channel KCCN, and suppressor of cyto-
kine signaling-1 (SOCS-1). Of these, KFL-2 and SOCS-1
are known to be negative regulators of cellular activa-
tion [51,52]. Stimulation with Ant alone revealed further
down-regulation of the genes in this cluster compared
to the Ag +Ant treatment (Figure 7, bottom panel). Taken
together, these data confirm that antagonism causes global
suppression of gene associated cell signaling andactivation along with induction of a smaller set of genes
associated with reduced activation.
Microarray data were analyzed with IPA pathway ana-
lysis software with a log fold change cutoff of a half log,
resulting in 481 and 383 molecules after Ag or Ag + Ant
treatments, respectively. Following upload, we looked at
the T cell receptor signaling canonical pathway with re-
spect to our dataset. The IPA database has 109 genes an-
notated in the TCR signaling canonical pathway, 16 of
which did not map to our dataset. However, of the
remaining 93 mapped genes, there were 48 genes that
were up-regulated and 45 genes down-regulated with Ag
treatment. In contrast, for Ag + Ant treatment there
were only 25 genes up-regulated and 68 genes that were
down-regulated. Furthermore, when all gene expression
changes were overlaid on the canonical pathway, the
Table 1 Genes differing by 2-fold or more expression between Ag and Ag + Ant treatment
Gene Fold change Function Reference
FOS 5.58 Immediate early gene transcription factor, up-regulated in response
to extracellular signals like chemokines and cytokines
CCL3L1 5.07 Codes for protein (Mip-1α) that binds CCR5 and caused internalization of CCR5, preventing HIV entry [34,35]
IL8 4.81 Inflammatory cytokine produced by T cells, cell chemoattractant
EGR2 4.75 Early growth response protein, responsible for regulation cell activation,
overexpression leads to inhibition of T cell activation
[36]
NR4A2 4.62 Involved in T cell homeostasis
NR4A3 4.33 Involved in T cell homeostasis
DUSP2 3.83 Phosphatase that inactivate MAP kinase cascade, negatively regulate proliferation and differentiation [37,38]
CSF2 3.49 Cell growth factor
TNFSF9 3.26 TNF superfamily trans-membrane glycoprotein expressed on activated T cells
MAP3K8 2.97 Activates MAP and JNK kinase pathways and induces NF-κB, promotes TNF-α and IL-2 during T cell activation [39,40]
TNF 2.96 Pro-inflammatory cytokine
CD69 2.94 Early inducible surface glycoprotein, functions as signal transducing receptor
EGR1 2.85 Early growth response protein, enhances T cell function [36]
SPRY1 2.77 Inhibits TCR signaling in differentiated cells, enhances TCR signaling in naïve cells [41]
IFNG 2.71 Pro-inflammatory cytokine, antiviral and immunoregulatory functions
TAGAP 2.63 Rho GTPase activating protein, role in T cell activation
FOSB 2.62 Proteins that dimerize with JUN, form AP-1 transcription complex, role in proliferation and differentiation [42]
CCL3 2.48 Pro-inflammatory cytokine (MIP-1α), natural ligand for CCR5 [43]
BTG2 2.47 Negative regulator of cell cycle [44]
GADD45B 2.44 Increased levels observed following cell stress, inhibit cell growth [45]
CCL3L3 2.44 Cytokine involved in immunoregulatory and inflammatory process, can bind to CCR5, inhibits HIV entry [34,35]
NR4A1 2.27 Can block activation through NF-κB, [46]
PDCD1 2.23 Negatively regulates TCR signals [47]
EGR4 2.17 Interacts with NF-κB, controls transcription of genes encoding inflammatory cytokines including IL-2 [48]
ZFP36 2.1 Binds to 3’-UTR of some cytokines and promotes their degradation [49]
PTGS2 2.09 Cox-2 has been shown to be Involved in Th1 differentiation
NFKBID 2.03 Member of NF-κB inhibitor family
FASLG 2.02 FAS-FASL binding is involved in T-cell homeostasis
FAM53C 2.00 Unknown function
GJB2 −2.13 Gap junction beta-2 protein
HBB −2.20 Haemoglobin beta subunit
SPDEY9P −2.25 Speedy/RINGO cell cycle regulator family member E9
CCR7 −2.28 G-protein coupled family receptor involved in T cell migration
Top up-regulated genes in gene array data.
Fold change was calculated and Ag + Ant was subtracted from Ag treatment. Data were then sorted from highest to lowest. The top genes that changed from Ag
compared to Ag + Ant treatment are shown. Data are presented in Log base 2.
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signaling could be compared for Ag (Additional file 1:
Figure S1) and Ag + Ant (Additional file 1: Figure S2)
conditions. There were considerable differences in the acti-
vation of the TCR signaling pathway. For example, several
genes (C-FOS, CD28, IκBα, FYN) were highly up-regulated
in the presence of the agonist but were down-regulated
compared to unstimulated cells after Ag +Ant treatment.In addition to the genes that went from up-regulated to
down-regulated, there were other genes, like CTLA4
and LAT, where the red color became less intense, indi-
cating attenuated up-regulation after Ag + Ant stimula-
tion. Stimulation with the Ant peptide resulted in
further down-modulation of genes in the TCR signaling
pathway compared to the Ag or Ag + Ant conditions
(Additional file 1: Figure S3). Taken together, these
AB
Figure 5 IPA Comparison analysis of gene array data. IPA comparison analysis was completed comparing Ag to Ag + Ant to Ant treatments.
Displayed are molecular and cellular functions and physiological system development functions that are associated with cellular signaling and
function and proliferation (A). Each pair of bars displays the most significantly associated function within that category that is over-represented
in the dataset. The larger the bar, the more strongly over-represented those functions were in the dataset. The p-values were determined by
right-tailed Fisher’s exact test with a p < 0.05 considered significant. Only over-represented functions or ones that have more associated molecules
than those are expected by chance are significant. Activation z-scores (calculated as described) for the 10 functions listed in Figure 6 that were
associated with T cell signaling and function are displayed (B). The p-values were determined by One-way analysis of variance followed by Tukey’s
multiple comparison test. *p < 0.05, **p < .01, ***p < .005.
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http://www.retrovirology.com/content/11/1/57observations represent decreased expression of a broad
array of genes and indicate an overall suppression of
TCR signaling when the antagonist is present.
In an independent study of T cell activation after SIV-
LAV vaccine challenge in macaques [53], a specific pat-
tern of gene expression representing T cell activation
was observed in antigen-specific memory CD4+ T cells
from the lymph nodes of protected macaques as early as
day 4 post challenge, but not in non-protected ma-
caques. Of note, the expression profile of the non-
protected macaques is likely not driven by differencesbetween the vaccine virus sequence and that of the chal-
lenge virus, as 2 of the 4 non-protected macaques and 8
of the 10 protected macaques received challenge with
virus homologous in sequence to the vaccine virus [53].
We compared the expression pattern of these genes fol-
lowing Ag or Ag +Ant treatment to that of the protected
(CP) and non-protected (NP) macaques (Figure 8). Of the
12 genes, 10 had the same expression trend in Ag vs. Ag +
Ant as compared to CP vs. NP macaques. Concordant
genes that are associated with T cell activation included
CD40LG, CTLA4, BTLA, TANK [54-56]. Conversely,
Yellow = Ag, Green = Ag + Ant, 








activation of T lymphocytes 2.93E-19 1.541 45
6.31E-04 0.179 18
6.09E-09 Decreased −3.854 53
differentiation of lymphocytes 1.67E-23 1.442 59
4.54E-04 −0.364 23
6.73E-08 −1.987 64
expansion of T lymphocytes 3.65E-11 1.565 20
3.05E-04 −0.057 10
6.40E-05 0.969 23
proliferation of lymphocytes 3.88E-24 0.736 74
9.01E-04 0.074 30
7.01E-16 −1.965 109
proliferation of T lymphocytes 9.20E-26 0.753 69
8.85E-04 −0.870 26
5.10E-17 −1.099 98
T cell homeostasis 3.94E-21 1.157 57
3.30E-04 −0.300 24
7.70E-12 −1.233 76
function of T lymphocytes* 8.27E-17 Increased 2.064 36
3.88E-06 −0.48 37
stimulation of leukocytes* 4.53E-13 Increased 3.173 24
2.44E-05 Decreased −2.971 24
stimulation of lymphocytes* 1.07E-14 Increased 3.128 22
6.92E-06 Decreased −2.296 22
stimulation of T lymphocytes* 1.74E-14 Increased 2.833 20
4.31E-06 Decreased −2.419 18
* These functions did not match to Ag + Ant condition with a significant p value.
Figure 6 Annotated biological functions associated with Hematological System Development and Function. Annotated functions in the
Hematological System Development and Function category that are associated with T lymphocytes with the number of molecules associated
with those functions are indicated. Activation z-score as determined based on expression data following core analysis with an expression value
cutoff of 0.5. Predicted activation state with activation z-score >2.0 or < −2.0. Yellow = Ag + Ant treatment, Green = Ag treatment.
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with activation in protected macaques and down-regulation
after Ag stimulation, though only LAG3 is associated
with T cell activation. Inclusion of data from Ant alone
stimulated cells showed that gene expression was distinct
from the other conditions, with Ant alone weakly group-
ing with the Ag and CP conditions (Additional file 2:
Figure S4). These data indicate that the gene expression
profile seen in T cell antagonism is similar to that of the
memory CD4+ T cells from vaccinated but non-protected
macaques.
Discussion
In this study we shed new light on the activation of
HIV-specific CD4+ T cell clones and the mechanism of
T cell antagonism. We demonstrated that by four hours
after stimulation, T cell activation was reduced at a global
level in the presence of antagonist peptide. Phosphoryl-
ation occurred transiently in the presence of agonist plus
antagonist peptides, but was attenuated and not sustained
compared to agonist peptide alone stimulation. These data
would be consistent with the antagonist peptide delivering
a dominant negative signal to block T cell activation. Sup-
porting this, the negative regulatory genes KFL-2, SOCS-
1, and SPDEY9P were down-regulated after Ag stimula-
tion and were in contrast up-regulated after Ag + Antstimulation. Additionally, overall T cell activation path-
ways were down-regulated after stimulation with antagon-
ist peptide, alone or in the presence of agonist peptide.
From prior work we know that antagonist peptide-
MHC can bind to the TCR in the system studied here
[27]. The initial induction of T cell signaling, including
STAT-3 and −5 phosphorylation, at early time points
with either Ag or Ag + Ant treatment supports delivery
of an early activation signal. However, signaling is only
sustained with the agonist alone condition, supporting
generation of a dominant negative signal by the antagon-
ist peptide (Figure 2). Although our data did not reach
statistical significance due to the variability in overall in-
tensity of the STAT signals, the differences observed
were also confirmed by multiplex testing that measured
the phosphorylation of STAT 3/5 (data not shown).
STAT-3 and STAT-5 are both implicated in transducing
signals delivered through the IL-2 receptor [30] and are
phosphorylated in T cells as a result of IL-2 autocrine
stimulation, so these data may reflect transient secretion
of IL-2 after Ag + Ant stimulation. Additionally, STAT-3
and −5 are important for TCR antigen stimulation and are
dependent on the MEK/ERK pathways [57]. Consistent
with the STAT phosphorylation data, measurement of cy-
tokines in culture supernatants showed a decrease in IL-2









Figure 7 Pathway analysis of gene array data. We selected annotated functions within the Hematological system development and function
category that were involved in all T cell functions and created a network from the 56 molecules represented in at least one of those functions.
Molecules were connected based on direct (solid lines) and indirect (dotted lines) interactions and sorted based on subcellular localization.
Expression values from Ag treatment, Ag + Ant treatment (Top Panels), and Ant treatment (Bottom Panel) were overlaid on the network, where
red indicates positive fold changes and green represent negative fold changes. Square = Cytokine, Rectangle = G-protein coupled receptor,
Dashed Rectangle = Ion Channel, Vertical Oval = Transmembrane Receptor, Horizontal Oval = Transcription regulator, Trapezoid = Transporter,
Diamond = Enzyme, Hexagon = Peptidase, Pentagon = Phosphatase, Triangle = Kinase, Circle = Other, * = multiple expression value identifiers
mapped to the same gene.
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http://www.retrovirology.com/content/11/1/57A large number of the down-regulated genes in the
Ag + Ant condition fell in the T cell signaling pathway,
including FOS, FOSB, and MAP3K8, which are key parts
in the MAPK and ERK pathways. These pathways lead
to activation and dimerization of the FOS and Jun tran-
scription factors, which form the AP-1 transcription factor
complex [42], and subsequent regulation of differentiation
and proliferation [58]. In addition to affecting these key
pathway regulators, antagonism decreased transcription of
genes coding for proteins responsible for T cell growth
(EGR2), T cell homeostasis (NR4A2/3) and cell growth
(CSF2). There were also several genes that were up-
regulated only after Ag +Ant stimulation. Of these genes,
CCR7, S1PR1, and KCCN are associated with T cell func-
tion and are induced by KLF-2 [59-61]. We observedincreased KLF-2 expression, and it is possible that there
was transient activation of Forkhead-Box transcription
factor-1 (FOXO1A) in the Ag + Ant treatment that was
not detected at four hours post-stimulation (data not
shown), as KLF-2 expression is induced by FOXO1A
[62,63]. Both FOXO1A and KLF-2 have been shown to
modulate T cell activation and have been implicated in ac-
tively suppressing T cell function [51,62,64,65].
An important aspect of T cell activation is the produc-
tion of cytokines and other molecules that mediate CD4+
T cell effector functions. We previously showed significant
decreases in IFN-γ and serine esterase production [26].
These data confirmed reduced production of IFN-γ after
Ag +Ant stimulation, and we also observed inhibition of
several pro-inflammatory cytokines, including TNFα,
Figure 8 Comparison with lymph node T cell responses of vaccinated macaques. Twelve genes were found to be differentially expressed in
non-protected vs. protected macaques, and z-scores for these genes in macaques and Ag and Ag + Ant stimulated T cells were used to generate
a heat map. A z-score was calculated for each gene and then mapped by gene and treatment. For the macaque data the z-scores for 10 CP
macaques and 4 NP macaques were averaged and mapped for comparison to Ag and Ag + Ant treatments. The clustering dendrogram was
generated based on a hierarchical clustering algorithm with completed linkage and Euclidian distance. CP = completely protected macaque,
NP = non-protected macaque.
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http://www.retrovirology.com/content/11/1/57MIP-1α/β, and IP-10, as well as chemotactic factors in-
volved in the inflammatory response (GM-CSF and IL-8).
In addition, the anti-inflammatory cytokine IL-10 was also
suppressed after Ag +Ant stimulation. Prior studies have
reported both increased [66,67] and decreased [68,69] IL-
10 secretion after altered peptide ligand exposure. The
mechanisms why some altered peptide ligands selectively
induce IL-10 secretion while suppressing other T cell
functions are not known but likely depend on the initial
induction of the antigen-specific T cell and its plasticity at
the time of stimulation.
The activation of SOCS1 in the Ag + Ant treatment is
potentially important due to its known effect on cyto-
kine signaling, as well as direct effects on T cell activa-
tion. SOCS1 has been shown to inhibit JAK tyrosine
kinase activity [52], which is consistent with the signifi-
cant reduction in STAT3/5 phosphorylation observed
(Figure 2). Additionally, SOCS1 has been associated with
modulation of T cell activation, where absence of SOCS1
leads to aberrant T cell activation [70,71]. Thus in Ag +
Ant treatment, activation of SOCS1 could limit cytokine
production as well as truncate T cell activation. Of simi-
lar importance is the increased expression of cell cycleregulating gene SPDEY9P. The RINGO/Speedy proteins
are known to activate certain cyclin-dependent kinases,
playing a critical role in cell-cycle progression and prolifer-
ation [72]. It was also found that SPDEY9P actually impairs
cell cycle progression, acting as a negative regulator of cel-
lular proliferation and cell cycle [44]. Thus, it is apparent
that along with the down-regulation of multiple signaling
pathways, Ag +Ant treatment also initiates a unique sig-
naling cascade that activates negative regulators of cell
cycle and proliferation including KFL-2 and SPDEY9P as
well as cytokine production including SOCS1.
Interestingly, we saw a similar gene expression pattern
in Ag vs. Ag + Ant as compared to CP vs. NP macaques
in the previously published SIV-LAV vaccine study. In
this study the early time point (4 days post challenge)
observed in the CP vs. NP macaques, where viral load
differences are not driving variation in the immune re-
sponse, is reflective of what an effective antigen-specific
immune response should look like, and T cell activation
and NF-κB activity is important to this response. We
showed above that following Ag +Ant treatment several
members of the NF-κB signaling pathway were down-
regulated, leading to the reduced expression of pro-
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http://www.retrovirology.com/content/11/1/57inflammatory cytokines. In addition to this, in both NP
macaques and Ag +Ant treatment we saw reduced expres-
sion of two key activators of NF-κB, TANK and RIPK2
[54,73]. We also saw similar reductions in CD40LG and the
serine protease GZMM which both play a role in T cell ac-
tivation and function of CD4 T cells. The reason for the
similarity between the immune responses in non-protected
macaques and Ag +Ant stimulated T cells is not clear.
Since half the non-protected macaques received a challenge
virus that matched the sequence of the vaccine [53], it is
unlikely that sequence variation caused antagonism of T
cells in the macaques. It is, however, notable that the effect-
ive vaccine response grouped with Ag stimulated T cells,
and it would be of interest to determine if a T cell gene sig-
nature of an effective (or conversely ineffective) T cell re-
sponse could be defined in studies of humans with good
and poor control of HIV, as this would be a useful metric
in assessing vaccine potency and potential for protection.
Conclusions
In summary, this study demonstrated a broad reduction
at the gene level of many factors associated with T cell
activation, proliferation and function. In this system the
antagonist peptide truncated activation induced by agon-
ist peptide, consistent with delivery of a dominant nega-
tive signal. These data were corroborated with pathway
analyses that demonstrated not only a global reduction
in T cell receptor signaling, but also a global reduction
in expression of a host of other genes that are involved
in T cell proliferation, induction, activation, function and
stimulation, along with the induction of a smaller set of
genes implicated in suppressing T cell activation and
function. We also provided a link to an existing vaccine
study where Ag + Ant treatment elicited similar re-
sponses to those seen in vaccine failure. Thus, small
changes to epitopes induced by HIV can have dramatic
effects on CD4+ T cell function, highlighting an import-
ant obstacle to HIV vaccine development.
Methods
Study subject
Subject AC-25 was infected with HIV in 1998 and started
highly active antiretroviral therapy within three months of
seroconversion. The CD4+ T cell clone was derived from a
sample obtained during a structured therapy intervention
18 months after infection. Samples were obtained with
informed consent, and the studies were approved by the
Massachusetts General Hospital Institutional Review Board.
Peptides
The 16 amino acid agonist peptide PP16 (PEVIPMF-
SALSEGATP) and 13 amino acid antagonist peptide
PG13 (PEVIPMFSALSEG) were obtained from Gen-
emed Synthesis.Maintenance of CD4+ T cell clone and B cell line
The CD4+ T cell clone and autologous Epstein-Barr
virus (EBV)-immortalized B cell line was derived as pre-
viously described [25]. The clones were cultured in
RPMI media (UCSF Cell Culture Facility (CCF)) supple-
mented with penicillin/streptomycin (UCSF-CCF), HEPES
(UCSF-CCF) and 20% fetal bovine serum (Hyclone) (R20)
with 20x106 gamma-irradiated peripheral blood mono-
nuclear cells (PBMC) (90 Gy) and 50 IU/mL IL-2. Clones
were re-stimulated every 2 weeks with fresh, irradiated
feeder PBMC and 12 F6 (anti-CD3 antibody obtained
from Johnson Wong, The Massachusetts General Hos-
pital, 0.1 μg/mL) or purified anti-CD3 antibody (Clone
UCHT-1, eBiosciences, 0.01 μg/mL). Autologous B cell
lines were EBV transformed in the presence of cyclo-
sporine A as previously described [25]. Cells were fed
twice weekly with R20 and IL-2 (50 IU/ml).
Antagonism assay
B cells were washed, counted and then pulsed for 1 hr
with 0.1 μg/mL PP16. Cells were then washed and cul-
tured 1:1 with T cell clones in the presence or absence of
antagonist peptide (PG13) at 10 μg/ml for indicated
times at 2x106 cell/mL (250 μL total volume). For intra-
cellular cytokine assays 10 μg/mL Brefeldin-A (Sigma
Aldrich) was added after 1 hr of co-culture. Following
co-culture, cells were washed and surface stained as in-
dicated with Aqua Amine viability dye, CD3, CD4 and
CD8, and then intracellularly stained for Phospho-Stat-3
and −5, or for IFN-γ. To ensure antagonism was present
prior to further downstream analysis, 4 hr co-culture ex-
periments to measure IFN-γ production were performed
in parallel. For detection of secreted cytokines, co-cultures
were incubated for indicated times without Brefeldin-A.
Following incubation, cells were pelleted and supernatants
were harvested and frozen at −80°C until analysis by
multiplex assay. For detection of phosphorylated protein
by multiplex assay, cells were co-cultured for indicated
time points in 50 μL total volume in 96-well v-bottom
dishes. Cells were washed with ice cold phosphate buff-
ered saline (PBS) containing Halt phosphatase/protease
inhibitor cocktail (Pierce), lysed with 50 μL Milliplex map
lysis buffer (Millipore) and frozen at −80°C until analysis
by multiplex assay. As CD4+ T cells were shown to be able
to present antigen to themselves, in the microarray experi-
ments the T cell clones were incubated with PP16 in the
presence or absence of PG13 antagonist peptide without
peptide-pulsed antigen presenting B cells to ensure that
only T cell mRNA was extracted.
Flow cytometry
Following co-culture cells were washed with PBS and
pelleted. Cells were first labeled with Aqua Amine viability
dye (Invitrogen) for 30 minutes and then subsequently
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CD4-BV421 (Biolegend) for 20 minutes. Cells were fixed
and permeabilized with Caltag regents (Invitrogen). Stain-
ing for IFN-γ was performed using IFN-γ-APC (Biole-
gend) for 30 minutes. Cells were acquired on an LSR II
flow cytometer (Becton Dickinson); 15,000 events per
condition were collected.
Phosflow
Following co-culture, cells were immediately fixed with
BD Lyse/Fix buffer for 10 minutes (BD Biosciences),
washed and then pelleted. Cells were then surfaced
stained with CD4 Pacific Blue and CD8-APC H7 (BD
Biosciences) for 20 minutes. For phosphorylated STAT-3
and −5 detection, samples were permeabilized with ice
cold BD Perm Buffer III for 30 minutes, washed with
PBS, and then incubated with phospho-STAT3 Alexa
Fluor 488 or PE and phospho-STAT-5 Alexa Fluor 647
for 30 minutes. Cells were acquired on an LSR II flow
cytometer (BD Biosciences); 50,000 events per condition
were collected.
Proliferation
To measure the ability of T cells to proliferate in response
to peptide presented by B cells or T cells, proliferation was
measured by 3H incorporation. T cell clones and B cells
were each plated in triplicate wells at 50,000 cells/well in
96 well plates in R10. After 48 hours, 1 μCi of 3H-thymi-
dine (Dupont Nen) in 50 μl R10 was added per well. Plates
were harvested onto glass fiber filters after 18 hours and
counts were obtained on a MicroBeta counter (Wallac).
Results were expressed as stimulation index (SI), the ratio
of counts from wells with antigen divided by the counts
obtained from wells without antigen.
Microarray
AC-25 clones were incubated with PP16 (without B cells)
in either the presence or absence of antagonist peptide
PG13 for 4 hours. Following incubation cells were flash
frozen for microarray analysis. Total RNA was isolated
using RNeasy Micro kits (Qiagen) and the quantity and
quality confirmed using a NanoDrop 200 c (Thermo
Fisher Scientific) and gel electrophoresis (Experion). Sam-
ples (50 ng) were amplified using Illumina TotalPrep RNA
amplification kits (Ambion). Microarray analysis was con-
ducted using 1.5 μg of biotinylated cRNA hybridized on
Illumina Human WG-6 Expression Bead Chips (v2.0, Illu-
mina) and then scanned on Illumina BeadStation 500GX.
Raw data was collected with Illumina GenomeStudio soft-
ware. Each hybridization was performed in triplicate. The
data sets were pre-processed with quantile normalization,
variance stabilization, and log2 transformation. Benjamini-
Hochberg correction was employed to assess the occur-
rence of false positives by calculating the false discoveryrate. Hierarchical clustering by Pearson’s correction and
heatmap representations were generated using MultiEx-
periment Viewer v4.6.2 (Dana Farber Cancer Institute). In-
genuity Pathway Analysis v9 (IPA) (Ingenuity Systems) was
used to select, annotate and visualize genes by function,
network and canonical pathway.
Multiplex cytokine assay
For detection of secreted cytokines, sample supernatants
were assayed using the human cytokine/chemokine pre-
mixed 39-plex kit (Millipore) for epidermal growth fac-
tor (EGF), eotaxin, fibroblast growth factor (FGF)-2,
Flt-3 ligand, fractalkine, G-CSF, GM-CSF, GRO, IFN-α2,
IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-
17, IL-1Rα, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-
7, IL-8, IL-9, IP-10, monocyte chemotactic protein
(MCP)-1, MCP-3, macrophage-derived chemokine (MDC),
macrophage inflammatory protein (MIP)-1α, MIP-1β,
TGF-α, TGF-β, vascular endothelial growth factor (VEGF),
sCD40L, and sIL-2Rα following the manufacturer’s
protocols. Standard curves and samples were run in
duplicate. A Labscan 100 analyzer (Luminex) and Bio-Plex
manager 4.1 (BioRad) were used to acquire samples. For
detection of phosphorylated proteins, a Milliplex MAP-
mates kit (Millipore) was used for phospho-STAT-1
(Tyr701), phospho-STAT-3 (Tyr705), phospho-STAT-
5A/B (Tyr694/Tyr699), phospho-STAT-6 (Tyr641), phospho-
c-Jun (Ser73), phospho-AKT/PKB (Ser473), phospho-JNK/
SAPK1 (Thr183/Tyr185), phospho-p38/SAPK1 (Thr180/
Tyr182), phospho-p70 S6 kinase, and phospho-IkBα
(Ser32) according to manufacturer’s protocols.
Area under the curve (AUC) at each time point was
calculated for agonist (Ag) and agonist plus antagonist
(Ag + Ant) treatment over a 240-minute period using
concentration data from four equal 60 minute time in-
tervals. The following variables and formula were used:
Expn ¼ cytokine concentration at time point n for the Ag or Ag
þ Ant experimental condition
Unstimn ¼ cytokine concentration of the unstimulated
condition at time point n
AUCn ¼ area under the curve from time point n to nþ 1
AUCT ¼ the sum of the AUC for each of the four time
intervals total AUCð Þ
AUCn ¼ Expn þ Expnþ1
 
− Unstimn þUnstimnþ1ð Þ
 
=2
Percent suppression for each cytokine was calculated
using the following:
% Suppression ¼ AUCTAg‐AUCTAgþ Antð Þ=AUCTAgð Þ  100
Jacobs et al. Retrovirology 2014, 11:57 Page 14 of 16
http://www.retrovirology.com/content/11/1/57Ingenuity Pathway Analysis
BeadArray data were exported to Microsoft Excel and all
required calculations [Ag – (Ag + Ant)] and organization
were completed, and the resulting dataset was uploaded
to IPA. Functional enrichment analysis was used to
analyze the each treatment in the dataset. Genes were
selected for pathway analysis using a log fold change
cutoff of a half log (i.e. 1.4 fold change). This resulted in
431 and 383 analysis-ready molecules for Ag and Ag +
Ant treatments respectively. We did a side-by-side com-
parison of the enrichment analysis results and analyzed
the biological functions that were most over-represented
in our datasets. The p-value associated with a specific
biological process or function was calculated by IPA
software and is a measure of the likelihood that mole-
cules in the dataset that overlap with those functions do
not occur by chance. The p-value was generated using a
right-tailed Fisher’s exact test [74], and only over repre-
sented functions (ones that are significant) were dis-
played. The p-values displayed show the annotated
function that has the most significant p-value for that
category. The software also calculated a z-score, which
represents a weighted sum based on evidence from the
literature for the activating and inhibitory pattern of
gene expression for a given function, to measure the net
effects on broader biological functions, such as T cell
proliferation. Up-regulation of genes associated with ac-
tivation of a function (e.g. proliferation of T lympho-
cytes) or down-regulation of genes associated with
inhibition of a function is predicted to be activating for
that function, and the converse is true for inhibition of a
function.Rhesus macaque gene expression data
The human gene expression data from the current work
were compared to data obtained in a prior study of live
attenuated SIV vaccines in rhesus macaques [53]. The
details of the animals are included in the prior work,
and the animals were used with approval of the Oregon
National Primate Research Center’s Animal Care and
Use Committee under the standards of the NIH Guide
for the Care and Use of Laboratory Animals [53]. To
normalize the gene expression data across the two spe-
cies, Z-scores were calculated for each macaque or each
treatment (e.g. Ag or Ag + Ant) on a gene by gene basis
as follows:
score ¼ gene expression value for each individual
macaque or treatment
mean ¼ average gene expression of all macaques or
treatmentsstandard deviation ¼ standard deviation of the mean
gene expression for all macaques
or treatments
Z-scores for each gene were calculated using the
following:
Z ¼ score‐meanð Þ=standard deviation
Statistical analysis
Comparison of the number of up-regulated and down-
regulated genes across stimulation conditions was per-
formed using a Kruskal-Wallis test followed by Dunn’s
Multiple Comparison Test. Analysis of protein phos-
phorylation and cytokine data was performed using two-
way analysis of variance (ANOVA) with Bonferroni’s
correction for multiple comparisons. Comparison of T
cell stimulation with and without B cells present was
performed using generalized estimating equations (GEE).
Statistical tests were performed using GraphPad Prism
and R-Bioconductor software. p-value <0.05 was consid-
ered significant.
Additional files
Additional file 1: Figures S1–S3. T cell receptor signaling pathway
analysis. Log-fold change was calculated from gene array mean
fluorescence intensity data. Fold-change values were uploaded to
Ingenuity Systems pathway analysis software. All expression values from
the data set for genes associated with T cell receptor signaling were
overlaid on the canonical pathway and compared. Fold-change values
from Ag treatment (Left Panel) and Ag + Ant treatment (Right Panel)
were overlaid on the T-cell receptor signaling canonical pathway. Red
indicates positive fold-changes and green represents gene negative
fold-changes. Molecules without an outline or color were not annotated
in our dataset or fell below the expression threshold cutoff. The color
scale was truncated at +/− 1.5 log-fold change.
Additional file 2: Figure S4. Comparison with lymph node T cell
responses of vaccinated macaques including Ant alone treatment.
Twelve genes were found to be differentially expressed in non-protected
vs. protected macaques, and z-scores for these genes in macaques and
Ag, Ag + Ant, Ant stimulated T cells were used to generate a heat map.
A z-score was calculated for each gene and then mapped by gene and
treatment. For the macaque data the z-scores for 10 CP macaques and
4 NP macaques were averaged and mapped for comparison to T cell
clone treatments. The clustering dendrogram was generated based on
a hierarchical clustering algorithm with completed linkage and Euclidian
distance. CP = completely protected macaque, NP = non-protected macaque.
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